Autoimmunity Biosolutions

Executive Summary

Autoimmunity Biosolutions (ABS) is a private, preclinical-stage biotechnology company headquartered in San Diego, CA, founded in 2016. The company is pioneering precision immunocorrective therapies for autoimmune disease patients who carry a specific genetic variant (SNP) in the Interleukin-7 Receptor pathway. This patient subpopulation does not respond adequately to standard-of-care treatments, representing a significant unmet medical need. ABS's lead program targets the soluble IL-7 receptor (sIL7R), a key driver of pathogenic immune responses in this genetically defined group. By focusing on a biomarker-selected population, ABS aims to increase efficacy and reduce systemic immunosuppression compared to traditional biologics.

Upcoming Catalysts (preview)

• Q4 2026Presentation of preclinical in vivo efficacy data for lead anti-sIL7R antibody80% success
• Q1 2027IND-enabling studies initiation for lead candidate70% success
• H2 2027Series B financing or strategic partnership to advance to clinic50% success